Business
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
Largest multinational survey highlights impact of pruritus on quality of life for patients with primary sclerosing cholangitis FOSTER CITY, Calif.--(BUSINESS
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nLargest multinational survey highlights impact of pruritus on quality of life for patients with primary sclerosing cholangitis\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented data at the International Liver Congress™ of The European Association for the Study of the Liver (EASL) in London, United Kingdom. The first analysis featured a multinational survey of patient-reported outcomes showing the effects of pruritus in patients with primary sclerosing cholangitis (PSC). A second poster assessed gastrointestinal (GI) tolerability on time of dosing with ileal bile acid transporter inhibitors (IBATis) relative to meals.\n\n“We are pleased to share new data at the 2022 EASL congress,” said Dr. Pam Vig, head of research and development at Mirum. “The large multinational PSC survey shows that adults with PSC often experience significant and debilitating pruritus which impacts their day-to-day quality of life, despite use of off-label antipruritic medications. Thus, there remains an urgency for a treatment to address this most burdensome symptom, and we are excited to be evaluating the potential of volixibat, a minimally absorbed IBAT inhibitor, in patients with PSC.”\n\nSummaries of data presented during the congress are enclosed below. View the presentations in full within our Publications & Presentations section on our website.\n\nPoster 756: Impact of pruritus in primary sclerosing cholangitis (PSC): a multinational survey\nBy Dr. Kris Kowdley, et al.\n\nThe multinational survey, conducted by Hetz Israel, PSC Australia, PSC Partners, and PSC Support, assessed results from a collection of patient-reported outcomes from people living with PSC (n=482). The aim of the survey was to assess the presentation and severity of cholestatic pruritus and its broader burden on patients with this rare liver disease. The 39-question survey captured the age and gender of respondents as well as whether they also have inflammatory bowel disease. In addition to pruritus, inflammatory bowel disease and chronic liver disease associated with PSC can negatively impact the quality of life and can lead to depression and anxiety.\n\nThe survey results showed that:\n\n\nOf the 91% of patients who reported experiencing itch following their diagnosis, 46.4% of respondents experienced >15 episodes (an episode ...